



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 26, 2025

Markus Warmuth, M.D.
Chief Executive Officer
Monte Rosa Therapeutics, Inc.
321 Harrison Avenue, Suite 900
Boston, MA 02118

Re: Monte Rosa Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 20, 2025
File No. 333-285942

Dear Markus Warmuth M.D.:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Kristen McCarthy, Esq.